AlterDiag

ALTERDIAG was founded in 2024 with a mission to develop and market innovative lateral-flow immunochromatographic tests to provide healthcare professionals who interact with patients with efficient, easy-to-use, and economically accessible diagnostic tools. These tools are designed to enable epidemiological screening of infectious diseases, aiming to combat or prevent new epidemics or pandemics. AlterDiag aspires to be internationally recognized as an innovative company and a scientific leader in the field of rapid diagnostic tests. R&D is thus central to its activities, and the company is building partnerships with prominent players at the forefront of biotechnological research. In parallel, AlterDiag has established commercial partnerships with manufacturers who share its values of excellence and innovation, in order to provide its clients with the best rapid membrane tests in the in-vitro diagnostic market.